Record branded sales collided with a cut to profit guidance and a failed trial.
HROW Harrow, Inc.
XNAS
30.12
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
HROW
$30.12
—
What changed
Recent filings, trades and movesKey stats
$30.12
- 52-Week Range
- $25.76 – $54.85
- YTD
- -39.65%
- IV Rank (30D)
- 52.41
- Straddle Price
- $5.40
- P/C Vol Ratio
- 0.17
- Market Cap
- $1.0B
- Open
- $29.88
- Day Range
- $29.25 – $30.52
- Volume
- 52,827
- Prev Close
- $30.36
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.86% |
| Beta vs SPY | 1.23 |
| Cost of Equity (CAPM) | 11.64% (VRP-adj) |
| WACC | 10.23% |
| Volatility Risk Premium | +25.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -1.4% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | -244.9% |
| Book / Price | 1.3% |
| Gross Margin (TTM) | 73.3% |
| FCF Margin (TTM) | 1.8% |
| Debt / Equity | 19.70 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $31.30 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $28.29 |
| Bollinger Width / SMA20 | 14.2% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $1B |
Peers used for multiples: JNJ, LLY, MANE, RPRX, SUPN, VTRS, XERS, ZTS
60-Day Conviction
61%
20-Day Fair Value
≈ by Dec 10, 2026
$30.28
α -0.3%
rank 29%
conviction
21%
40-Day Fair Value
≈ by Jan 8, 2027
$31.14
α +2.6%
rank 34%
conviction
73%
60-Day Fair Value
≈ by Feb 8, 2027
$31.10
α +2.5%
rank 28%
conviction
61%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $-4.07 | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 43.9× · 4 peers |
| Peer EV/EBITDA | $4.87 | 8% | median 21.3× · 7 peers |
| Peer P/B | $3.31 | 10% | median 8.3× · 7 peers |
| Peer P/S | $50.47 | 10% | median 6.8× · 7 peers |
| Market Anchor (SMA50) | $31.30 | 45% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $30.02 | 26% | 25 strikes · skew +0.05 |
As of 2026-11-11 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.0B
- Employees
- 373
- List Date
- 2007-04-30
- CIK
- 0001360214
- Last Earnings
- Nov 9 after close · +10.5% vs ±17.8% expected
- Next Earnings
- ~Mar 1, 2027 (estimated)
- Headquarters
- Nashville, TN
- Homepage
- https://www.harrow.com
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-3…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 22.45% | -13.39% | 1.62% | -20.25% | -15.97% | -17.97% | -7.25% |
| Feb | -14.59% | -3.02% | 18.13% | 13.59% | -5.87% | 20.67% | 4.82% |
| Mar | -14.66% | -10.26% | 15.31% | 20.82% | 3.78% | -34.20% | -3.20% |
| Apr | 12.96% | -0.44% | 20.31% | -20.39% | -0.84% | 14.39% | 4.33% |
| May | 18.71% | 5.55% | -27.07% | 72.10% | 12.44% | -13.91% | 11.30% |
| Jun | -3.13% | 0.28% | -2.41% | 22.67% | 1.87% | 24.51% | 7.30% |
| Jul | -1.87% | -5.88% | 20.29% | 22.47% | 3.22% | -10.09% | 4.69% |
| Aug | 18.17% | 33.19% | -28.17% | 64.81% | 24.88% | -5.58% | 17.88% |
| Sep | -10.36% | 35.92% | -7.23% | 13.45% | 27.73% | -16.69% | 7.14% |
| Oct | 10.88% | -6.16% | 3.13% | 1.37% | -21.91% | -7.74% | -3.40% |
| Nov | -4.58% | -9.94% | -31.38% | -8.17% | 16.18% | 7.66%* | -5.04% |
| Dec | -13.34% | 22.49% | 20.30% | -19.85% | 23.18% | -- | 6.56% |
| Total | 10.50% | 40.10% | -19.12% | 214.28% | 71.55% | -43.90% | 45.57% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $28.29
SMA 50: $31.30
SMA 200: $37.71
Current: $30.36
EMA 12: $28.38
EMA 26: $29.19
MACD: -0.8048 | Signal: 0.2714
BEARISH
ADX (14): 39.87
TREND
+DI: 35.17
−DI: 24.01
Momentum Oscillators
RSI (14): 54.95
NEUTRAL
Stoch %K: 40.30
Stoch %D: 29.27
Williams %R: -41.92
Volume & Volatility
BB Upper: $30.30
BB Lower: $26.28
OVERBOUGHT
OBV: -3,895,267
Vol SMA 20: 683,327
Vol ROC: 238.82%
ATR: $1.78
True Range: $6.21
HV 20: 66.4%
HV 30: 56.3%
HV 60: 50.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before HROW’s Nov 9 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary BULLISH (Confidence Level: 6/10)
Key Drivers:
- Oversold RSI reading suggests potential buying opportunity
- Recent news headlines pointing towards positive sentiment
Primary Risks:
- High volatility, indicating increased uncertainty
- Bearish MACD signal may lead to further price decline
Investment Thesis: HROW presents a moderate-risk buying opportunity with potential for short-term gains. The oversold RSI and recent positive news sentiment create an attractive entry point.
Recent News Sentiment Impact: The negative headlines from last 10 articles have been overshadowed by the more recent positive news, shifting the overall sentiment towards neutral/positive.
Technical Analysis Trend Direction: BEARISH (Short-term), NEUTRAL (Medium-term)
Support/Resistance Levels:
- Lower Bollinger Band: $24.71
- Middle Bollinger Band: $41.00
Momentum Signals: RSI interpretation: Oversold (<30) - potential buying opportunity MACD signal: Bearish, indicating further price decline possible Bollinger Bands position: Mean reversion expected
Volume Analysis: Volume trend: Decreasing Institutional interest signals: Weak
News & Sentiment Analysis Recent Headlines Summary:
- Opaleye-managed account sells Harrow shares (Negative)
- Braidwell LP decreases stock position in Harrow (Neutral)
- Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (Negative)
- ...and 5 more recent headlines
Sentiment Assessment: NEUTRAL
Catalyst Identification:
- No upcoming earnings or product launches
- Regulatory changes: None reported
Market Narrative: The news sentiment has shifted towards neutral/positive, contradicting the bearish MACD signal. This divergence may indicate a potential buying opportunity.
Risk & Volatility Assessment Beta Interpretation: High-risk stock relative to market (beta >1.5)
Volatility Regime: High volatility - stock moves more than market
Options Market Signals:
- IV rank: 31.6% (Medium)
- Put/call ratios: Bearish sentiment
- Unusual activity: None reported
Downside Protection: Support levels: Lower Bollinger Band ($24.71), Middle Bollinger Band ($41.00)
Market Context & Positioning Sector Performance:
- Relative strength vs sector/market: Weak
Institutional Activity:
- Volume patterns suggesting institutional interest signals: Weak
Correlation Analysis:
- How stock moves relative to market (R-squared interpretation): Low correlation
Relative Valuation: Position within trading range: Neutral
Key Levels & Action Items Critical Price Levels:
- Lower Bollinger Band ($24.71), Middle Bollinger Band ($41.00)
Breakout/Breakdown Levels:
- Technical levels that could trigger significant moves: SMA 20 ($41.00), EMA 12 ($36.56)
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches: None reported
Risk Management: Stop-loss levels and position sizing considerations: Based on the high volatility and bearish MACD signal, consider implementing a stop-loss at the lower Bollinger Band ($24.71) or Middle Bollinger Band ($41.00).
Generated
News
All HROW news →
Earnings History
11 of 19 under expected move
Avg Expected Move
14.64%
Avg Actual Move
15.34%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-08 | After-Close | 3.74% | 2.49% | 0.67x | Within |
| 2021-11-09 | After-Close | 6.97% | 5.05% | 0.72x | Within |
| 2022-11-14 | After-Close | 5.17% | 4.57% | 0.88x | Within |
| 2023-03-23 | After-Close | 15.77% | 6.78% | 0.43x | Within |
| 2023-05-11 | After-Close | 13.59% | 18.58% | 1.37x | Exceeded |
| 2023-07-18 | After-Close | 5.75% | 17.84% | 3.10x | Exceeded |
| 2023-11-13 | After-Close | 15.98% | 36.01% | 2.25x | Exceeded |
| 2024-03-19 | After-Close | 17.46% | 1.22% | 0.07x | Within |
| 2024-05-13 | After-Close | 17.56% | 34.55% | 1.97x | Exceeded |
| 2024-08-07 | After-Close | 15.58% | 54.32% | 3.49x | Exceeded |
| 2024-11-14 | After-Close | 7.47% | 8.98% | 1.20x | Exceeded |
| 2025-03-17 | After-Close | 24.66% | 15.69% | 0.64x | Within |
| 2025-05-08 | After-Close | 20.98% | 3.43% | 0.16x | Within |
| 2025-08-11 | After-Close | 19.93% | 3.23% | 0.16x | Within |
| 2025-11-10 | After-Close | 20.43% | 13.47% | 0.66x | Within |
| 2026-03-02 | After-Close | 19.31% | 27.96% | 1.45x | Exceeded |
| 2026-05-11 | After-Close | 15.25% | 23.69% | 1.55x | Exceeded |
| 2026-08-10 | After-Close | 14.86% | 3.14% | 0.21x | Within |
| 2026-11-09 | After-Close | 17.75% | 10.52% | 0.59x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
HROW Options Activity & IV Rank
HROW IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 71.5%
7-DTE IV: 95.9%
Expected Move: $5.40
7-DTE Move: $3.85
Days to Exp: 37 (2026-12-18)
Options Flow · All expiries
Call Volume: 6,122
Put Volume: 1,038
P/C Volume: 0.17
BULLISH
Call OI: 54,789
Put OI: 5,957
P/C OI: 0.109
Total OI: 60,746
ATM Options Pricing
ATM Call: $2.45
ATM Put: $2.95
Call %: 8.1%
Put %: 9.8%
Chain Summary
Chain Volume: 7,160
Chain OI: 60,746
Last Updated: 11/11/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 65th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
65%
vs own history
GEX tilt
+0.50
OI-weighted, today
Vanna tilt
+0.55
δ-sensitivity to IV
Charm tilt
-0.65
δ-decay vs time
Vanna tilt +0.55: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.65: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 30 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)35.2MediumNov 11
IV Rank (30 DTE)52.4MediumNov 11
Straddle Price (30 DTE)$5.40Nov 11
Beta Analysis
Risk Metrics
Beta: 1.4271
Alpha: -5.13%
Correlation: 0.3047
R-Squared: 9.3%
Stock Volatility: 64.0%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own HROW
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $15.3M | #1298 of 6285 | +62.6% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $3.6M | #2257 of 3716 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.9M | #1980 of 3138 | -47.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $15K | #3837 of 4729 | +72.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
HROW Institutional Ownership (13F)
Filings for 2026-06-30 · 78 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 36,735,814 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$76.15M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $31.55M | 41.43% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $16.62M | 21.83% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $10.17M | 13.35% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $8.69M | 11.41% | 2026-09-30 |
| 5 | Jane Street Group, LLC Custodian | $7.77M | 10.21% | 2026-06-30 |
| 6 | Private Capital Management, LLC | $743.23K | 0.98% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $609.84K | 0.80% | 2026-09-30 |
8 filers$26.13M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $9.90M | 37.88% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $7.83M | 29.96% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $3.57M | 13.65% | 2026-09-30 |
| 4 | Jane Street Group, LLC Custodian | $2.00M | 7.66% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $1.32M | 5.06% | 2026-06-30 |
| 6 | Squarepoint Ops LLC | $925.85K | 3.54% | 2026-06-30 |
| 7 | TUDOR INVESTMENT CORP ET AL | $420.45K | 1.61% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $169.40K | 0.65% | 2026-09-30 |
HROW Insider Trading (Form 4)
Latest: 2026-08-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Amir Shojaei | CHIEF SCIENTIFIC OFFICER | Mixed Sell −11,250 · Exer +11,250 |
— | $37.98 | -$45.5K | EDGAR |
| 2026-06-22 | Lauren P Silvernail | Director | Grant (A) | +5,248 RSU | — | EDGAR | |
| 2026-06-22 | Adrienne L Graves | Director | Grant (A) | +5,248 RSU | — | EDGAR | |
| 2026-06-22 | Perry J. Sternberg | Director | Grant (A) | +5,248 RSU | — | EDGAR | |
| 2026-05-19 | Lauren P Silvernail | Director | Buy (P) | +1,000 | $31.00 | $31.0K | EDGAR |
| 2026-05-19 | Adrienne L Graves | Director | Buy (P) | +1,000 | $31.07 | $31.1K | EDGAR |
| 2026-05-18 | Amir Shojaei | CHIEF SCIENTIFIC OFFICER | Grant (A) | +10,000 RSU | — | EDGAR | |
| 2026-05-15 | Andrew R. Boll | PRESIDENT AND CFO | Buy (P) | +3,500 | $29.90 | $104.7K | EDGAR |
| 2026-05-15 | Mark L Baum | CHIEF EXECUTIVE OFFICER | Buy (P) | +10,000 | $30.20 | $302.0K | EDGAR |
| 2026-03-05 | Opaleye Management Inc. | 10%+ Owner | Sell (S) | −198,572 | $39.51 | -$7.85M | EDGAR |
| 2026-03-03 | Opaleye Management Inc. | 10%+ Owner | Sell (S) | −5,000 | $54.18 | -$270.9K | EDGAR |
| 2026-02-02 | Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | Grant (A) | +40,000 RSU | — | EDGAR | |
| 2026-01-08 | Opaleye Management Inc. | 10%+ Owner | Sell (S) | −20,000 | $53.35 | -$1.07M | EDGAR |
| 2025-12-16 | Mark L Baum | CHIEF EXECUTIVE OFFICER | Mixed Exer +180,000 · Tax −79,994 |
+100,006 | $17.21 | -$3.05M | EDGAR |
| 2025-12-16 | Andrew R. Boll | PRESIDENT AND CFO | Mixed Exer +60,000 · Tax −26,665 |
+33,335 | $17.21 | -$1.02M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
HROW Insider Holdings
6 insiders · @ $30.36
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 10%+ Owner | 3,756,000 | $114.03M | -$6.77M | 9 | 2026-03-05 |
| 2 | Mark L Baum | CHIEF EXECUTIVE OFFICER | 3,594,256 | $109.12M | $302.0K | 10 | 2026-05-15 |
| 3 | Andrew R. Boll | PRESIDENT AND CFO | 814,679 | $24.73M | $104.7K | 9 | 2026-05-15 |
| 4 | Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 11,250 | $341.6K | -$450.0K | 2 | 2026-08-17 |
| 5 | Lauren P Silvernail | Director | 1,000 | $30.4K | $31.0K | 2 | 2026-06-22 |
| 6 | Adrienne L Graves | Director | 1,000 | $30.4K | $31.1K | 2 | 2026-06-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
HROW Board & Officers
As of SEC filings through Aug 17, 2026Directors 4
- Mark L Baum · since Dec 12, 2011
- Perry J. Sternberg · since Mar 31, 2022
- Adrienne L Graves · since Jan 26, 2024
- Lauren P Silvernail · since Jan 26, 2024
Officers 6
- Mark L Baum · Chief Executive Officer · since Dec 12, 2011
- Francis William Mullery Jr · CEO, ImprimisRx · since Oct 6, 2025
- Andrew R. Boll · President and CFO · listed since Dec 2025
- Amir Shojaei · Chief Scientific Officer · since Jan 6, 2025
- Randall E. Pollard · Chief Accounting Officer · since Sep 1, 2025
- Patrick William Sullivan · Chief Commercial Officer · since Jan 30, 2026
10% owners 1
- Opaleye Management Inc. (entity) · listed since May 2020
Changes in the last 10 years (23)
| Jan 30, 2026 | Patrick William Sullivan became Chief Commercial Officer |
| Dec 16, 2025 | Mark L Baum no longer listed as a 10% owner in SEC filings |
| Dec 16, 2025 | Andrew R. Boll listed as President and CFO (previously Chief Financial Officer) in SEC filings |
| Oct 6, 2025 | The company announced the departure of John P. Saharek as CEO of ImprimisRx in an SEC filing |
| Oct 6, 2025 | Francis William Mullery Jr became CEO, ImprimisRx |
| Sep 1, 2025 | Randall E. Pollard became Chief Accounting Officer |
| Apr 7, 2025 | Mark L Baum first listed as a 10% owner in an SEC filing |
| Jan 17, 2025 | The company announced the departure of Martin A. Makary from the board in an SEC filing |
| Jan 6, 2025 | Amir Shojaei became Chief Scientific Officer |
| Feb 21, 2024 | John P. Saharek listed as CEO of ImprimisRx (previously Chief Commercial Officer) in SEC filings |
| Jan 26, 2024 | Lauren P Silvernail became a director |
| Jan 26, 2024 | Adrienne L Graves became a director |
| Nov 3, 2023 | The company announced the departure of R. Lawrence Van Horn from the board in an SEC filing |
| Apr 4, 2023 | John P. Saharek listed as Chief Commercial Officer (previously President, ImprimisRx) in SEC filings |
| Mar 31, 2022 | The company announced the departure of Robert J Kammer from the board in an SEC filing |
| Mar 31, 2022 | The company announced the departure of Robert J Kammer as Chairman of the Board in an SEC filing |
| Mar 31, 2022 | Perry J. Sternberg became a director |
| Mar 31, 2022 | Martin A. Makary became a director |
| Feb 23, 2021 | John P. Saharek listed as President, ImprimisRx (previously Chief Commercial Officer) in SEC filings |
| Sep 28, 2020 | R. Lawrence Van Horn became a director |
| May 22, 2020 | Opaleye Management Inc. first listed as a 10% owner in an SEC filing |
| Mar 16, 2020 | Teresa Sparks became a director |
| Apr 13, 2017 | Clayton D Edwards became Chief Operating Officer |
Not reported recently (5)
- Teresa Sparks · Last reported as a director in an SEC filing dated Jun 23, 2023
- Richard L Md Lindstrom · Last reported as a director in an SEC filing dated Oct 3, 2022
- Anthony Principi · Last reported as a director in an SEC filing dated Sep 30, 2020
- Stephen G Austin · Last reported as a director in an SEC filing dated Mar 18, 2020
- Clayton D Edwards · Last reported as Chief Operating Officer in an SEC filing dated Apr 17, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
HROW Proposed Insider Sales (Form 144)
Latest: 2026-08-21
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $450K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
AMIR SHOJAEI (1, $450K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-21 | AMIR SHOJAEI | CHIEF SCIENTIFIC OFFICER | 11,250 | $450.0K | 2026-08-14 | MORGAN STANLEY SMITH BARNEY | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-09
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-09 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-10-05 | Material agreement · Acquisition or sale completed · Regulation FD disclosure | EDGAR |
| 2026-09-04 | Director or officer change | EDGAR |
| 2026-08-10 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-08-06 | Material agreement · Regulation FD disclosure | EDGAR |
| 2026-06-22 | Shareholder vote results | EDGAR |
| 2026-06-03 | Regulation FD disclosure | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
53 ETFs hold HROW
25 shown · $130.85M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $30.8M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $23.2M | $77.8B | 2026-11-09 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $11.1M | — | 2026-09-30 |
| 4 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.13% | $8.8M | $6.8B | 2026-11-09 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.06% | $8.3M | $14.1B | 2026-11-09 |
| 6 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 1.45% | $7.2M | $495.3M | 2026-11-09 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.02% | $6.2M | — | 2026-11-09 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.03% | $5.8M | — | 2026-08-31 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.8M | — | 2026-09-30 |
| 10 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.18% | $3.1M | $1.7B | 2026-11-09 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $3.0M | — | 2026-09-30 |
| 12 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.7M | — | 2026-11-09 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.22% | $2.7M | $1.2B | 2026-11-09 |
| 14 | PSC Principal U.S. Small-Cap ETF | Nport | 0.10% | $2.3M | — | 2026-06-30 |
| 15 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.3M | — | 2026-11-09 |
| 16 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.3M | $95.3B | 2026-11-09 |
| 17 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.06% | $1.1M | — | 2026-09-30 |
| 18 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.03% | $983,234 | $3.2B | 2026-11-09 |
| 19 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.02% | $958,758 | $4.3B | 2026-11-09 |
| 20 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.09% | $939,776 | $1.1B | 2026-11-09 |
| 21 | DUSG Dimensional US Small Cap Growth ETF | Dimensional | 0.04% | $783,307 | — | 2026-11-09 |
| 22 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $758,035 | — | 2026-11-09 |
| 23 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $723,510 | — | 2026-08-31 |
| 24 | BSJU Invesco BulletShares 2030 High Yield Corporate Bond ETF | Invesco | 0.17% | $565,643 | — | 2026-11-09 |
| 25 | RSSL Global X Russell 2000 ETF | Global X | 0.03% | $469,730 | — | 2026-11-10 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.97
TTM Revenue
$275.59M
TTM Net Income
$-37.23M
TTM Op. Cash Flow
$6.25M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $70.66M | $-17.27M | $-0.46 | $-9.76M |
| Q1 '26 | 2026-03-31 | $44.20M | $-27.60M | $-0.74 | $-8.99M |
| Q4 '25 | 2025-12-31 | $89.09M | $6.63M | $0.18 | $8.41M |
| Q3 '25 | 2025-09-30 | $71.64M | $1.02M | $0.03 | $16.59M |
| Q2 '25 | 2025-06-30 | $63.74M | $5.00M | $0.13 | $-803.00K |
| Q1 '25 | 2025-03-31 | $47.83M | $-17.78M | $-0.50 | $19.67M |
| Q4 '24 | 2024-12-31 | $66.83M | $6.78M | $0.19 | $-17.78M |
| Q3 '24 | 2024-09-30 | $49.26M | $-4.22M | $-0.12 | $2.95M |
| Q2 '24 | 2024-06-30 | $48.94M | $-6.47M | $-0.18 | $-2.75M |
| Q1 '24 | 2024-03-31 | $34.59M | $-13.56M | $-0.38 | $-4.63M |
| Q4 '23 | 2023-12-31 | $36.35M | $-9.15M | $-0.27 | $8.70M |
| Q3 '23 | 2023-09-30 | $34.27M | $-4.39M | $-0.13 | $-1.21M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
75.13
P/S
4.05
EV/EBITDA
72.28
EV/Sales
4.80
ROE
-250.8%
ROA
-8.9%
Div Yield
0.00%
FCF Yield
0.56%
Debt/Equity
19.70
Current Ratio
—
Market Cap
$1.12B
as of 2026-11-10
HROW vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.26T | 46.5 | +45.5% | +32.6% | 27 |
| JNJ Johnson & Johnson | $679.1B | 42.6 | +7.8% | +35.4% | 57 |
| ZTS ZOETIS INC. | $33.4B | 13.7 | +2.6% | −34.5% | 3 |
| RPRX Royalty Pharma plc Class A Ordinary Shar | $30.6B | 49.3 | +11.4% | +78.7% | 54 |
| VTRS Viatris Inc. Common Stock | $23.5B | — | +4.3% | +67.3% | 46 |
| MANE Veradermics, Incorporated | $6.0B | — | — | +293.2% | 0 |
| XERS Xeris Biopharma Holdings, Inc. Common St | $2.9B | — | +38.4% | +115.4% | 21 |
| SUPN Supernus, Inc. Common Stock | $1.6B | — | +26.9% | −41.9% | 13 |
| HROW Harrow, Inc. Common Stock | $1.0B | — | +21.1% | −39.2% | 32 |
| Peer median | $27.1B | 44.5 | +11.4% | +51.4% | 24 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.47M
SI % of Float
24.27%
Days to Cover
11.23
Short Vol Ratio
63.6%
Free Float
30.80M
Float %
82.2%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-24